Search research articles
Contact Us
Filters
Showing results (281-290 of 318) with videos related to
Page
of 32
Sort By:
Molecular Metabolism
|
April 4, 2019
Discovering metabolic disease gene interactions by correlated effects on cellular morphology
Yang Jiao, Umer Ahmed, M F Michelle Sim, et al.
Gastroenterology
|
February 7, 2016
The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent
Rosellina Margherita Mancina, Paola Dongiovanni, Salvatore Petta, et al.
Cell Metabolism
|
May 1, 2018
DGAT2 Inhibition Alters Aspects of Triglyceride Metabolism in Rodents but Not in Non-human Primates
David G McLaren, Seongah Han, Beth Ann Murphy, et al.
Journal of Pediatric Hematology/Oncology
|
March 2, 2022
Guideline for Children With Cancer Receiving General Anesthesia for Procedures and Imaging
Kaitlin J Devine, Caroline Diorio, Sarah A Richman, et al.
British Journal of Pharmacology
|
September 25, 2009
Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia
J Tammam, C Ware, C Efferson, et al.
Cancer Research
|
February 11, 2010
MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor
Bo-Sheng Pan, Grace K Y Chan, Melissa Chenard, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
November 9, 2022
Pediatric Aggressive Mature B-Cell Lymphomas, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Matthew Barth, Ana C Xavier, Saro Armenian, et al.
Journal of Medicinal Chemistry
|
February 6, 2013
Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met
Alan B Northrup, Matthew H Katcher, Michael D Altman, et al.
JCO Oncology Practice
|
September 19, 2025
AML Care at Home: An Evidence-Based Toolkit to Personalize the Care Setting for Recovery From Pediatric AML Chemotherapy
Alix E Seif, Sara L McDonough, Emily M Becker-Haimes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2009
Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks
Diane Palmieri, Paul R Lockman, Fancy C Thomas, et al.
Page
of 32
Search research articles
Search
Showing results (281-290 of 318) with videos related to
Sort By:
Page
of 32
Molecular Metabolism
|
April 4, 2019
Discovering metabolic disease gene interactions by correlated effects on cellular morphology
Yang Jiao, Umer Ahmed, M F Michelle Sim, et al.
Gastroenterology
|
February 7, 2016
The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent
Rosellina Margherita Mancina, Paola Dongiovanni, Salvatore Petta, et al.
Cell Metabolism
|
May 1, 2018
DGAT2 Inhibition Alters Aspects of Triglyceride Metabolism in Rodents but Not in Non-human Primates
David G McLaren, Seongah Han, Beth Ann Murphy, et al.
Journal of Pediatric Hematology/Oncology
|
March 2, 2022
Guideline for Children With Cancer Receiving General Anesthesia for Procedures and Imaging
Kaitlin J Devine, Caroline Diorio, Sarah A Richman, et al.
British Journal of Pharmacology
|
September 25, 2009
Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia
J Tammam, C Ware, C Efferson, et al.
Cancer Research
|
February 11, 2010
MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor
Bo-Sheng Pan, Grace K Y Chan, Melissa Chenard, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
November 9, 2022
Pediatric Aggressive Mature B-Cell Lymphomas, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Matthew Barth, Ana C Xavier, Saro Armenian, et al.
Journal of Medicinal Chemistry
|
February 6, 2013
Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met
Alan B Northrup, Matthew H Katcher, Michael D Altman, et al.
JCO Oncology Practice
|
September 19, 2025
AML Care at Home: An Evidence-Based Toolkit to Personalize the Care Setting for Recovery From Pediatric AML Chemotherapy
Alix E Seif, Sara L McDonough, Emily M Becker-Haimes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2009
Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks
Diane Palmieri, Paul R Lockman, Fancy C Thomas, et al.
Page
of 32